iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally.
The last earnings update was 40 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
iZafe Group. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
iZafe Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
iZafe Group's earnings are expected to grow significantly at over 20% yearly.
iZafe Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
iZafe Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Anders Segerström serves as the CEO at MediRätt AB (publ) since 2019. Mr. Segerström has been in leading company roles in the fields of business development, sales and management since 2005. In 2017, Anders Segerström became CEO of Sensec Personlig Säkerhet, which he grew into a profitable company that was acquired by MediRätt before changing name to iZafe. Previously, Anders was head of business development at the same company, and before then head of sales at the broadband provider Net1. Mr. Segerström has a degree in Business Management from the IHM Business School.
Insufficient data for Anders to compare compensation growth.
Insufficient data for Anders to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the iZafe Group management team is less than 2 years, this suggests a new team.
Chief Executive Officer
Chief Operating Officer
Chief Operating Officer
Head of Sales & VP
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the iZafe Group board of directors is about average.
Board of Directors
Chairman of the Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. The company offers Dosell, a drug dispenser for homecare that reminds patients when to take medication and triggers an alarm if a patient fails to do so. It also provides MediKoll, an app that offers patients information about side effects, reactions, and allergies related to various types of medication. The company offers its products for the pharmaceutical, hospital and care home, and pharmacy and private healthcare markets. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was founded in 2008 and is based in Lidingö, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.